Last reviewed · How we verify
NCT05839418: SENSEII/AROUSE
Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)
trial in Status Epilepticus in 3,000 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Erasme University Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 1 March 2023 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 11 locations across Denmark, Finland, Belgium, Austria, United Kingdom, Germany, Norway, Switzerland |
Conditions studied
- Status Epilepticus — all drugs for Status Epilepticus →
Sponsor
Erasme University Hospital
Who can join
18 and older, any sex, with Status Epilepticus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SENSE-II/AROUSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to document patients and SE characteristics, treatment modalities, EEG features, and outcome of consecutive adults admitted fir SE treatment in each of the participating centers and to identify predictors of outcome and refractoriness.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Sustained effort network for treatment of status epilepticus/European academy of neurology registry on adult refractory status epilepticus (SENSE-II/AROUSE).
Damien C, Leitinger M, Kellinghaus C, Strzelczyk A, et al · · 2024 · cited 3× · PMID 38178048 · DOI 10.1186/s12883-023-03505-y
Verify or expand the search:
- PubMed search for NCT05839418
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Status Epilepticus
Currently open trials in the same condition.
- NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
- NCT06194747 — Improving Status Epilepticus Treatment Times · NA · recruiting
- NCT06017973 — The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus · NA · recruiting
- NCT05851391 — buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest · Phase 2 · recruiting
- NCT05674552 — Exogenous Ketone Esters for Refractory Status Epileptics · Phase 2, PHASE3 · recruiting
Other Erasme University Hospital trials
Trials by the same sponsor.
- NCT07532733 — Respiratory and Haemodynamic Effects of Conscious Sedation With Dexmedetomidine for a TAVI Procedure · NA · not yet recruiting
- NCT07532681 — Effect of Early Versus Late Surgical Intercostal Block on Postoperative Pain Relief Following Video-Assisted Thoracic Su · NA · not yet recruiting
- NCT07457879 — Impact of the Reimbursement of Fibrinogen in Cardiac Surgery · not yet recruiting
- NCT07184593 — Nucleosome Monitoring Relevance for Outcome Prediction in Critically Ill Patients · not yet recruiting
- NCT07369232 — Cerebral Hemodynamic Effects of Oxygen and Antioxidants (CHEOXANT) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05839418 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erasme University Hospital
- Last refreshed: 3 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05839418.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing